Drug discovery at SCYNEXIS

The complex process of transforming a hit into a clinical candidate requires a broad range of technical skills and capabilities. SCYNEXIS Discovery Research incorporates Medicinal Chemistry, Analytical Chemistry, ADMET-PK and Bioanalytical Chemistry into fully-integrated SCYNEXIS Research Teams to meet specific project demands for our global client base.  SCYNEXIS adds value to our collaborators by incorporating networks of consultants to drive projects and by using new technologies in key disease areas such as ophthalmology and dermatology.  We provide risk sharing business models to maximize value for our collaborators and introduce novel biological targets from our proprietary Cyclophilin Inhibitor platform.

SCYNEXIS’ Fully-Integrated Research Teams

Our Research Team leaders are industry-recognized scientists with proven track records in major pharmaceutical and biotech companies including GSK, Merck, AstraZeneca, Sanofi-Aventis, Eli Lilly, Dupont and Pfizer.  Projects are staffed with seasoned professionals, with more than half holding Ph.D. degrees and averaging more than 10 years of industrial experience.  Effective project management and client communication are hallmarks of the SCYNEXIS approach, applied to collaborations on both the local level and on a global scale.

Success with SCYNEXIS

With more than 50 Medicinal Chemists on staff, SCYNEXIS has the size and experience to handle projects of any complexity and has been involved in the selection of multiple preclinical and clinical candidates across a variety of therapeutic areas and targets including:

As of 2012, we have delivered 11 preclinical and 6 clinical candidates to clients and partners.  Our fully-integrated approach including Discovery Biology, ADMET-PK, Bioanalytical, Process Chemistry  and cGMP API Manufacturing seamlessly transitions your compounds from hit seeking, hit-to-lead and lead optimization through to candidate selection, process scale-up and clinical material manufacturing:
From Concept To Clinic With Speed and Innovation™.